Inventiva S.A. (NASDAQ:IVA - Get Free Report)'s stock price traded up 1.3% during mid-day trading on Monday . The stock traded as high as $3.24 and last traded at $3.15. 7,314 shares changed hands during trading, a decline of 88% from the average session volume of 63,046 shares. The stock had previously closed at $3.11.
Analysts Set New Price Targets
Several research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Inventiva in a report on Friday, March 28th. TD Cowen initiated coverage on Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 price objective for the company. Finally, Guggenheim lowered their price objective on Inventiva from $12.00 to $9.00 and set a "buy" rating for the company in a research report on Friday, April 4th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Inventiva has a consensus rating of "Moderate Buy" and a consensus target price of $10.40.
Check Out Our Latest Analysis on Inventiva
Inventiva Stock Down 0.2%
The company's fifty day moving average is $3.29 and its two-hundred day moving average is $2.80.
Institutional Investors Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in Inventiva S.A. (NASDAQ:IVA - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm purchased 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
See Also
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
